- Research Letter
- Open Access
Beta-2-glycoprotein I as a biomarker for sepsis in critically ill patients in the intensive care unit: a prospective cohort study
Critical Care volume 24, Article number: 341 (2020)
To the editor,
It is difficult to diagnose sepsis in critically ill patients admitted to the intensive care unit (ICU). A biomarker could help in sepsis identification and guide antibiotic use. A prognostic biomarker that identifies high-risk patients for the development of sepsis or nosocomial infections could help prevent those outcomes. However, current sepsis biomarkers often portray systemic inflammation and are unspecific to infection .
The complement system is essential for defending against infections, yet it can also contribute to severe sepsis outcomes . A potential complement regulator is beta-2-glycoprotein I (B2GPI). B2GPI, also known as apolipoprotein H, exerts a complement control after binding to specific surfaces such as apoptotic cells and bacteria. After the conformational change of B2GPI, monocytes can clear B2GPI, resulting in lower B2GPI plasma levels. Supporting this, previous studies found lower levels of B2GPI after lipopolysaccharide (the main component of the outer membrane of bacteria) infusion in humans and male mice [3, 4]. Therefore, we hypothesized that B2GPI levels can differentiate between sepsis and non-infectious critically ill patients. To test this and to determine the discriminative and prospective value of B2GPI as a sepsis biomarker, we conducted a prospective study.
We included 313 critically ill adult patients (defined as two or more systemic inflammatory response syndrome (SIRS) criteria upon admission) with an anticipated ICU stay of more than 24 h (Table 1) . In 48 h following ICU admission, blood was sampled twice to measure the maximum level of B2GPI using a semi-automated sandwich ELISA on a Freedom EVO platform (Tecan) with goat anti-human beta-2-glycoprotein-1 and HRP-coupled goat-human beta-2-glycoprotein-1 antibodies (both Cedarlane). Supersignal West Pico Chemiluminescent substrate (Thermo Scientific) was added, and the luminescence signal was measured using a Spectramax-L microplate reader (MDS Analytical). The outcomes “no sepsis,” “sepsis,” and “septic shock” were defined according to the sepsis-3 criteria. The outcome “proven infection” was derived from Centers for Disease Control (CDC) algorithms. Statistical analyses were performed using SPSS version 21.0 and R version 3.6.1.
We found that B2GPI levels were significantly lower in patients with sepsis compared with patients without sepsis. Patients with a septic shock had lower B2GPI levels compared with patients with solely sepsis (Fig. 1a). Patients with an infection had lower levels of B2GPI (Fig. 1b). Patients within the highest tertile of B2GPI levels developed 44% fewer infections compared with the lowest tertile (P = 0.007, Fig. 1d) in the 10-day follow-up. There was no significant difference in B2GPI levels between survivors and non-survivors (Fig. 1c) and between gram-positive and gram-negative sepsis (162 [IQR 87–275] vs 131 [IQR 96–221]).
We showed that B2GPI could differentiate between patients with and without sepsis. Moreover, patients with lower B2GPI levels in the first 48 h developed more nosocomial infections. This suggests that B2GPI may be a novel biomarker for both diagnosing sepsis and predicting nosocomial infections. This study took place in a general ICU; therefore, it seems feasible that our results could be generalizable to other ICUs.
Most biomarkers spike in sepsis; therefore, the lower B2GPI levels we found are relatively unique. Other biomarkers that decrease in sepsis are the inter-alpha inhibitor protein, lysophosphatidylcholine, and uric acid [1, 6]. However, currently, they are not used in clinical practice.
In summary, this is the first study that showed the value of the B2GPI biomarker in ICU patients with both a discriminative (for sepsis) and predictive (for nosocomial infections) role. Potentially, B2GPI can be helpful in diagnosing sepsis and stratifying ICU patients for infection risk.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Centers for Disease Control
Intensive care unit
Systemic inflammatory response syndrome
Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. https://doi.org/10.1186/cc8872.
Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med. 2008;12(6A):2245–54.
El-Assaad F, Qi M, Gordon AK, Qi J, Dong S, Passam F, et al. Beta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner. Sci Rep. 2017;7(1)8201.
Agar C, de Groot PG, Morgelin M, Monk SD, van Os G, Levels JH, et al. β2-glycoprotein I: a novel component of innate immunity. Blood. 2011;117(25):6939–47.
Hyseni A, Kemperman H, de Lange DW, de Groot PG, Linssen M, Kesecioglu J, et al. Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. J Thromb Haemost. 2013;11(12):2111–7.
Mecatti GC, Messias MCF, de Oliveira Carvalho P. Lipidomic profile and candidate biomarkers in septic patients. Lipids Health Dis 2020 13;19(1):68.
The authors received no financial support for the research, authorship, and/or publication of this article.
Ethics approval and consent to participate
The study methods were submitted to and approved by the institutional review board of the University Medical Centre Utrecht. It waived the need for informed consent (University Medical Centre Utrecht Institutional Review Board research protocol 108–188). The study was conducted in accordance with the Declaration of Helsinki.
Consent for publication
The authors declare they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Schrijver, I.T., Kemperman, H., Roest, M. et al. Beta-2-glycoprotein I as a biomarker for sepsis in critically ill patients in the intensive care unit: a prospective cohort study. Crit Care 24, 341 (2020). https://doi.org/10.1186/s13054-020-03066-3
- Critical care
- Apolipoprotein H